Portal de Periódicos da CAPES

Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results

2017; Wiley; Volume: 14; Issue: 5 Linguagem: Inglês

10.1016/j.jalz.2017.10.005

1552-5279

Sonia Moreno–Grau, Octavio Rodríguez‐Gómez, Ángela Sanabria, Alba Pérez‐Cordón, Domingo Sánchez‐Ruiz, Carla Abdelnour, Sergi Valero, Isabel Hernández, Maitée Rosende‐Roca, Ana Mauleón, Liliana Vargas, Asunción Lafuente, Silvia Gil, Miguel A. Santos‐Santos, Montserrat Alegret, Ana Espinosa, Gemma Ortega, Marina Guitart, Anna Gailhajanet, Itziar de Rojas, Óscar Sotolongo‐Grau, Susana Ruiz, Núria Aguilera, Judith Papasey, Elvira Martín, Esther Pelejà, Francisco Lomeña, Francisco Campos, Assumpta Vivas, Marta Gómez‐Chiari, Miguel Ángel Tejero, Joan Giménez, Manuel Serrano‐Ríos, Adelina Orellana, Lluís Tárraga, Agustı́n Ruiz, Merçé Boada, Carla Abdelnour, N. Aguilera, Montserrat Alegret, Marcelo L. Berthier, Merçé Boada, Mar Buendía, Santiago Bullich, Francisco Campos, Pilar Cañabate, Claudia Cuevas, Itziar de Rojas, Ana Espinosa, A. Gailhajenet, S. Diego, Silvia Gil, Joan Giménez, Rossella Gismondi, Marta Gómez‐Chiari, M. Guitart, Begoña Hernández‐Olasagarre, Iván Hernández Ramírez, Marta Ibarria, A. Lafuente, F. Lomeña, E. Martín, Joan Martínez, Ana Mauleón, Gemma C. Monté, M. Moreno, Sonia Moreno–Grau, L. Núñez, Adelina Orellana, Gemma Ortega, Antonio Páez, Ana Pancho, Javier Pavı́a, E. Pelejà, Alba Pérez‐Cordón, Virginia Pérez‐Grijalba, Pedro Pesini, Silvia Preckler, Octavio Rodríguez‐Gómez, J. Romero, Maitée Rosende‐Roca, Ángela Gisselle Lozano Ruiz, Susana Ruiz, Ángela Sanabria, Domingo Sánchez‐Ruiz, Miguel A. Santos‐Santos, Manuel Sarasa, Óscar Sotolongo‐Grau, Lluís Tárraga, Miguel Ángel Tejero, María Fernanda Torres Calle, Sergi Valero, Liliana Vargas, Assumpta Vivas,

Neurological Disease Mechanisms and Treatments

Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored.We evaluated apolipoprotein E (APOE) ε4's effect in the risk of presenting SCD, using the Fundacio ACE Healthy Brain Initiative (FACEHBI) SCD cohort and Spanish controls, and performed a meta-analysis addressing the same question. We assessed the relationship between APOE dosage and brain amyloid burden in the FACEHBI SCD and Alzheimer's Disease Neuroimaging Initiative cohorts.Analysis of the FACEHBI cohort and the meta-analysis demonstrated SCD individuals presented higher allelic frequencies of APOE ε4 with respect to controls. APOE dosage explained 9% (FACEHBI cohort) and 11% (FACEHBI and Alzheimer's Disease Neuroimaging Initiative cohorts) of the variance of cerebral amyloid levels.The FACEHBI sample presents APOE ε4 enrichment, suggesting that a pool of AD patients is nested in our sample. Cerebral amyloid levels are partially explained by the APOE allele dosage, suggesting that other genetic or epigenetic factors are involved in this AD endophenotype.